CFS Clinical Selected C3i to Provide Technology Support Globally for their Proprietary Systems - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
CFS Clinical Selected C3i to Provide Technology Support Globally for their Proprietary Systems

Source: Company News Release

C3i, a global provider of service desk support and business process outsourcing (BPO) services for the life sciences industry, announced that it has been selected by CFS Clinical to provide global 24x365 multilingual technology support services for their Site Activation and Investigator Payment Services.

CFS Clinical is the leading technology-enabled service provider focused on site startup and investigator payments for clinical trials. The company was recently acquired by DrugDev – an interactive network and data sharing platform for 80,000+ clinical trial doctors worldwide. DrugDev and CFS’ combined capabilities create a powerful offering in finding, engaging and paying investigators.

The partnership between C3i and CFS Clinical started back in March 2013 with a training engagement. This included a 30-minute eLearning module developed in English and translated into a Spanish version. The high level of CFS’ satisfaction with the delivered training services led to expanding the partnership between the two companies, and as of February 28th, C3i is providing global 24x365 multilingual technology support services for CFS’ Site Startup and Global Payment Services systems. The service desk is supporting active clinical trial sites in nearly 50 countries and 12 languages, staffed out of C3i’s Sofia Operations Center. Later in 2014, additional languages will be added to manage CFS’ continued scaling, supported out of C3i’s Dalian Operations Center

”C3i’s industry and custom technology support expertise, reputation and global multilingual abilities were all factors that influenced our decision to select C3i in this endeavor. We already had a positive experience with C3i’s capabilities and professionalism, which they demonstrated by the earlier training development engagement”, said Greg Seminack, President of CFS Clinical. C3i’s ability to support proprietary applications was also a key factor in their selection of C3i as a partner.

“I am excited to welcome one of the leading specialty providers in the life sciences industry as our client,” said Joel Morse, CEO of C3i Inc. “C3i is fully committed to delivering a service desk support infrastructure that will ensure CFS’ customers worldwide receive the best experience with the company’s proprietary systems“.

 

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here